These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 11519433)

  • 1. [Lipid peroxidation and antioxidant defenses in neonates treated with exogenous surfactants].
    Dobrians'kyĭ DO
    Lik Sprava; 2001; (2):57-62. PubMed ID: 11519433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total antioxidant capacity and total oxidant status after surfactant treatment in preterm infants with respiratory distress syndrome.
    Dizdar EA; Uras N; Oguz S; Erdeve O; Sari FN; Aydemir C; Dilmen U
    Ann Clin Biochem; 2011 Sep; 48(Pt 5):462-7. PubMed ID: 21775575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surfactant therapy for respiratory distress syndrome in premature neonates: a comparative review.
    Ainsworth SB; Milligan DW
    Am J Respir Med; 2002; 1(6):417-33. PubMed ID: 14720029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention and treatment of respiratory distress syndrome in premature infants using intratracheally administered surfactants].
    de Winter JP; Egberts J; de Kleine MJ; van Bel F; Wijnands JB; Guit GL
    Ned Tijdschr Geneeskd; 1992 Oct; 136(41):2018-24. PubMed ID: 1407193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of respiratory mechanics in preterm babies after surfactant administration in the neonatal period.
    Parmigiani S; Panza C; Bevilacqua G
    Acta Biomed Ateneo Parmense; 1997; 68 Suppl 1():65-73. PubMed ID: 10021719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of lipid peroxidation of pulmonary surfactant by plasma of preterm babies.
    Moison RM; Palinckx JJ; Roest M; Houdkamp E; Berger HM
    Lancet; 1993 Jan; 341(8837):79-82. PubMed ID: 8093405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of severe respiratory distress syndrome with surfactant].
    Jacobsen T; Verder H; Skov L; Greisen GO; Friis-Hansen B
    Ugeskr Laeger; 1992 Jun; 154(23):1642-5. PubMed ID: 1631999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
    Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R;
    Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Observational study to compare the clinical efficacy of the natural surfactants Alveofact and Curosurf in the treatment of respiratory distress syndrome in premature infants.
    Proquitté H; Dushe T; Hammer H; Rüdiger M; Schmalisch G; Wauer RR
    Respir Med; 2007 Jan; 101(1):169-76. PubMed ID: 16698258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a necessity for multiple doses of surfactant for respiratory distress syndrome of premature infants?
    Tsakalidis C; Giougki E; Karagianni P; Dokos C; Rallis D; Nikolaidis N
    Turk J Pediatr; 2012; 54(4):368-75. PubMed ID: 23692717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surfactant substitution in ventilated very low birth weight infants: factors related to response types.
    Segerer H; Stevens P; Schadow B; Maier R; Kattner E; Schwarz H; Curstedt T; Robertson B; Obladen M
    Pediatr Res; 1991 Dec; 30(6):591-6. PubMed ID: 1805156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of preterm neonates with severe respiratory distress syndrome using exogenous natural surfactants of porcine origin].
    Valls i Soler A; López de Heredia I; Hernaéz Ortega E; Román Echevarría L; Gastiasoro Cuesta E; Robertson B
    An Esp Pediatr; 1992 May; 36(5):375-81. PubMed ID: 1616198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Superoxide dismutase and catalase activity in tracheobronchial secretions after surfactant treatment of newborn infants with respiratory distress syndrome].
    Schröder A; Herting E; Speer CP
    Z Geburtshilfe Neonatol; 1999; 203(5):201-6. PubMed ID: 10596413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of symptomatic patent ductus arteriosus with ethamsylate in babies treated with exogenous surfactant.
    Amato M; Hüppi P; Markus D
    J Perinatol; 1993; 13(1):2-7. PubMed ID: 8445442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surfactant replacement therapy in neonates with respiratory failure due to bacterial sepsis.
    Fetter WP; Baerts W; Bos AP; van Lingen RA
    Acta Paediatr; 1995 Jan; 84(1):14-6. PubMed ID: 7734891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia.
    Bassler D
    Neonatology; 2015; 107(4):358-9. PubMed ID: 26044104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surfactant: current and potential therapeutic application in infants and adults.
    Lewis J; Veldhuizen RA
    J Aerosol Med; 1996; 9(1):143-54. PubMed ID: 10160204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomized placebo-controlled multicenter study.
    Kari MA; Hallman M; Eronen M; Teramo K; Virtanen M; Koivisto M; Ikonen RS
    Pediatrics; 1994 May; 93(5):730-6. PubMed ID: 8165070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An observational study of surfactant treatment in infants of 23-30 weeks' gestation: comparison of prophylaxis and early rescue.
    Bevilacqua G; Parmigiani S;
    J Matern Fetal Neonatal Med; 2003 Sep; 14(3):197-204. PubMed ID: 14694975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surfactant replacement therapy for preterm and term neonates with respiratory distress.
    Polin RA; Carlo WA; ;
    Pediatrics; 2014 Jan; 133(1):156-63. PubMed ID: 24379227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.